Aerovate Therapeutics, INC 8-K filings

Jade Biosciences announced positive interim Phase 1 data for JADE101, a potential best-in-class therapy for IgA nephropathy, and provided a corporate update highlighting a strong cash runway into late 2028.

Jade Biosciences has entered into a material definitive agreement, securing an exclusive license for antibody technology from Paragon Therapeutics, Inc., with potential milestone payments and royalties.

Jade Biosciences has appointed industry veteran Dr. Mark Eisner to its Board of Directors to bolster clinical development expertise.

Jade Biosciences, Inc. announced the approval of amended Articles of Incorporation and Bylaws, including a jury trial waiver and updated voting standards, following its 2026 Annual Meeting.

Jade Biosciences has priced a public offering of 10,000,000 shares of common stock at $15.00 per share to raise approximately $140.3 million in net proceeds.

Jade Biosciences announced positive interim results from its Phase 1 trial of JADE101, an investigational antibody for IgA nephropathy, showing significant and sustained IgA reductions with a favorable safety profile.

Jade Biosciences announced Q1 2026 financial results, highlighting strong cash position and progress across its autoimmune disease therapy pipeline, with multiple Phase 1 and Phase 2 trials advancing.

Jade Biosciences, Inc. announced the appointment of Andrew King, Ph.D. as President, Research & Development, effective April 18, 2026.

Jade Biosciences, Inc. has approved a new 2026 Employment Inducement Stock Incentive Plan reserving 1.75 million shares for new hires.

Jade Biosciences announced its fourth quarter and full year 2025 financial results, highlighting a strong cash position and significant progress across its autoimmune disease pipeline.

Jade Biosciences announced its 2026 strategic priorities, including pipeline advancements for JADE101, JADE201, and JADE301, backed by an estimated $336 million cash runway into the first half of 2028.

Jade Biosciences, a clinical-stage biotech, announced a $45 million private placement of common stock with BB Biotech to fund R&D and working capital.

Jade Biosciences reported Q3 2025 financial results, highlighted significant pipeline advancements for JADE101 and JADE201, and announced a $135 million private placement extending its cash runway into H1 2028.

Jade Biosciences, a clinical-stage biotech, announced a $135 million private placement and unveiled JADE201, a new autoimmune disease candidate, extending its cash runway into 2028.

Jade Biosciences, Inc. announced the departure of Chief Medical Officer Dr. Hetal Kocinsky, effective September 9, 2025, with scientific programs continuing under Dr. Andrew King.

Jade Biosciences reported robust second-quarter 2025 financial results, highlighting a strong cash position and significant advancements in its autoimmune disease pipeline, including its lead candidate JADE101.

Jade Biosciences, Inc. has appointed Bradford Dahms as its new Chief Financial Officer and entered into a master services agreement with Patheon Biologics LLC for the development and manufacturing of its lead candidate, JADE101.

Jade Biosciences completed its reverse merger, commenced trading on Nasdaq as JBIO, and is advancing its lead candidate JADE101 towards clinical trials.

Jade Biosciences completes its merger with Aerovate Therapeutics and a $300 million private placement to advance its autoimmune disease therapies.

Jade Biosciences, formerly Aerovate Therapeutics, presents its corporate strategy focusing on developing best-in-class therapies for autoimmune diseases, particularly IgAN, with its lead candidate JADE-001.

Aerovate Therapeutics has revised the payment date for its special cash dividend, linked to the pending merger with Jade Biosciences, from April 29, 2025, to April 28, 2025, contingent upon the merger's completion.

Aerovate Therapeutics' stockholders have approved the proposed merger with Jade Biosciences, along with a reverse stock split at a ratio of 1-for-35.

Aerovate Therapeutics declares a special cash dividend of approximately $2.40 per share, totaling $69.6 million, contingent on the successful completion of its merger with Jade Biosciences.

Aerovate Therapeutics is addressing stockholder lawsuits and demand letters related to alleged misrepresentations in the Form S-4 filing for its merger with Jade Biosciences, while proceeding with supplemental disclosures to avoid delays.

Aerovate Therapeutics expects to declare a cash dividend in the range of $67.6 to $69.6 million to pre-merger stockholders in connection with the proposed merger with Jade Biosciences.

Aerovate Therapeutics and Jade Biosciences have agreed to merge, creating a company focused on advancing Jade's autoimmune disease therapies, supported by a $300 million financing.

Aerovate Therapeutics has regained compliance with Nasdaq listing rules regarding audit committee composition following the appointment of a new member.

Maha Katabi, Ph.D., has resigned from Aerovate Therapeutics' board of directors and its Audit and Compensation Committees, effective October 6, 2024.

Aerovate Therapeutics has announced a strategic review to maximize shareholder value, engaging Wedbush Securities as its financial advisor.

Aerovate Therapeutics is reducing its workforce by 78% after halting its Phase 2b/Phase 3 clinical trial of AV-101, incurring approximately $5.6 million in severance costs.